日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cerebral Oximetry-Guided Treatment and Cerebral Oxygenation in Extremely Preterm Infants: A Randomized Clinical Trial

脑氧饱和度指导治疗和脑氧合在极早产儿中的应用:一项随机临床试验

Jani, Pranav R; Goyen, Traci-Anne; Balegar, Kiran Kumar; Maheshwari, Rajesh; Saito-Benz, Maria; Schindler, Tim; Moore, James; Merhi, Manelle; Cruz, Melinda; Song, Yang; McDonagh, Hayley; Luig, Melissa; Tracy, Mark; D'Cruz, Daphne; Perdomo, Aldo; Morakeas, Stephanie; Dasireddy, Vishnu; Culcer, Mihaela; Shingde, Vijay; Bennington, Karen; Michalowski, Joanna; Fucek, Andreja; Querim, Jennifer; Stevens, Sean; Santanelli, James; Elhindi, James; Gloss, Brian; Halliday, Robert; Shah, Dharmesh; Popat, Himanshu

Serum Hepatocyte Growth Factor Concentration Correlates with Albuminuria in Individuals with Optimal Blood Pressure and Untreated Arterial Hypertension

血清肝细胞生长因子浓度与血压正常且未经治疗的高血压患者的蛋白尿呈正相关

Fistrek Prlic, Margareta; Vukovic Brinar, Ivana; Kos, Jelena; Dika, Zivka; Ivandic, Ema; Fucek, Mirjana; Jelakovic, Bojan

Selection of bispecific antibodies with optimal developability using FcRn‑Ph‑HPLC as an optimized FcRn affinity chromatography method

使用 FcRn-Ph-HPLC 作为优化的 FcRn 亲和层析方法选择具有最佳可开发性的双特异性抗体

Thomas Müller, Carolin Tasser, Michael Tesar, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch, Kristina Ellwanger

Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell Engagers

与先天细胞接合剂预复合的自然杀伤细胞的冷冻保存

Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Thomas Müller, Ute Schniegler-Mattox, Joachim Koch, Michael Tesar

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

AFM24 的临床前评估,这是一种针对 EGFR 阳性肿瘤的新型 CD16A 特异性先天免疫细胞接合剂

Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Michael Kluge, Michael Damrat, Jens Pahl, Ute Schniegler-Mattox, Thomas Mueller, Ivica Fucek, Kristina Ellwanger, Michael Tesar, Torsten Haneke, Joachim Koch, Martin Treder, Wolfgang Fischer, Erich Rajkovic

Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity

重定向优化细胞杀伤 (ROCK®):一种高度通用、多特异性、适合用途的抗体平台,用于参与先天免疫

Kristina Ellwanger, Uwe Reusch, Ivica Fucek, Susanne Wingert, Thorsten Ross, Thomas Müller, Ute Schniegler-Mattox, Torsten Haneke, Erich Rajkovic, Joachim Koch, Martin Treder, Michael Tesar

Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies

TandAb 抗体高度特异性和有效地靶向 EGFRvIII 阳性肿瘤

Kristina Ellwanger, Uwe Reusch, Ivica Fucek, Stefan Knackmuss, Michael Weichel, Thorsten Gantke, Vera Molkenthin, Eugene A Zhukovsky, Michael Tesar, Martin Treder

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells

一种四价双特异性TandAb(CD19/CD3),AFM11,能够有效募集T细胞,从而强效裂解CD19(+)肿瘤细胞。

Uwe Reusch ,Johannes Duell, Kristina Ellwanger, Carmen Herbrecht, Stefan Hj Knackmuss, Ivica Fucek, Markus Eser, Fionnuala McAleese, Vera Molkenthin, Fabrice Le Gall, Max Topp, Melvyn Little, Eugene A Zhukovsky

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells

一种四价双特异性TandAb(CD19/CD3),AFM11,能够有效募集T细胞,从而强效裂解CD19(+)肿瘤细胞。

Uwe Reusch,Johannes Duell, Kristina Ellwanger, Carmen Herbrecht, Stefan Hj Knackmuss, Ivica Fucek, Markus Eser, Fionnuala McAleese, Vera Molkenthin, Fabrice Le Gall, Max Topp, Melvyn Little, Eugene A Zhukovsky

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells

新型四价双特异性 TandAb (CD30/CD16A) 可有效募集 NK 细胞以裂解 CD30+ 肿瘤细胞

Uwe Reusch, Carmen Burkhardt, Ivica Fucek, Fabrice Le Gall, Mikaelle Le Gall, Karin Hoffmann, Stefan H J Knackmuss, Sergej Kiprijanov, Melvyn Little, Eugene A Zhukovsky